In the period 2018 to 2022, a total of approximately *** men per 100,000 inhabitants died of cancers of all kinds in the United States, compared to an overall cancer death rate of *** per 100,000 population among women. This statistic shows cancer death rates in the U.S. for the period from 2018 to 2022, by type and gender.

From 2018 to 2022, the overall death rate for lung and bronchus cancer in the United States was 38.7 per 100,000 for males and 27.6 per 100,000 for females. This statistic presents the death rates for lung and bronchus cancer in the United States from 2018 to 2022, by gender and race/ethnicity.

BackgroundCervical cancer incidence and mortality rates in the United States have substantially declined over recent decades, primarily driven by reductions in squamous cell carcinoma cases. However, the trend in recent years remains unclear. This study aimed to explore the trends in cervical cancer incidence and mortality, stratified by demographic and tumor characteristics from 1975 to 2018.MethodsThe age-adjusted incidence, incidence-based mortality, and relative survival of cervical cancer were calculated using the Surveillance, Epidemiology, and End Results (SEER)-9 database. Trend analyses with annual percent change (APC) and average annual percent change (AAPC) calculations were performed using Joinpoint Regression Software (Version 4.9.1.0, National Cancer Institute).ResultsDuring 1975–2018, 49,658 cervical cancer cases were diagnosed, with 17,099 recorded deaths occurring between 1995 and 2018. Squamous cell carcinoma was the most common histological type, with 34,169 cases and 11,859 deaths. Over the study period, the cervical cancer incidence rate decreased by an average of 1.9% (95% CI: −2.3% to −1.6%) per year, with the APCs decreased in recent years (−0.5% [95% CI: −1.1 to 0.1%] in 2006–2018). Squamous cell carcinoma incidence trends closely paralleled overall cervical cancer patterns, but the incidence of squamous cell carcinoma in the distant stage increased significantly (1.1% [95% CI: 0.4 to 1.8%] in 1990–2018). From 1995 to 2018, the overall cervical cancer mortality rate decreased by 1.0% (95% CI: −1.2% to −0.8%) per year. But for distant-stage squamous cell carcinoma, the mortality rate increased by 1.2% (95% CI: 0.3 to 2.1%) per year.ConclusionFor cervical cancer cases diagnosed in the United States from 1975 to 2018, the overall incidence and mortality rates decreased significantly. However, there was an increase in the incidence and mortality of advanced-stage squamous cell carcinoma. These epidemiological patterns offer critical insights for refining cervical cancer screening protocols and developing targeted interventions for advanced-stage cases.

In the period from 2018 to 2022, around 15 per 100,000 males in the United States died due to colorectal cancer. This statistic displays the colorectal cancer mortality rate among U.S. residents from 2018 to 2022, by gender.

This statistic shows the number of breast cancer deaths in the United States from 1999 to 2021, by gender. The highest number of breast cancer deaths in the given period was 42,465, reported in 2018. The lowest number was reported in 2008, with 40,589 deaths.

The role of religion and politics in the responses to the coronavirus pandemic raises the question of their influence on the risk of other diseases. This study focuses on age-adjusted death rates of cancer, heart disease, and infant mortality per 1000 live births before the pandemic (2018-2019) and COVID-19 in 2020-2021. Eight hypothesized predictors of health effects were analyzed by examining their correlation to age-adjusted death rates among U.S. states, percentage who pray once or more daily, Republican influence on state health policies as indicated by the percentage vote for Trump in 2016, percent of household incomes below poverty, median family income divided by a cost-of-living index, the Gini income inequality index, urban concentration of the population, physicians per capita, and public health expenditures per capita. Since prayer for divine intervention is common to otherwise diverse religious beliefs and practices, the percentage of people claiming to pray daily in each state was used to indicate potential religious influence. All of the death rates were higher in states where more people claimed to pray daily, and where Trump received a larger percentage of the vote. Except for COVID-19, the death rates were consistently lower in states with higher public health expenditures per capita. Only COVID-19 was correlated to physicians per capita, lower where there were more physicians. Corrected statistically for the other factors, income per cost of living explains no variance. Heart disease and COVID-19 death rates were higher in areas with more income inequality. All of the disease rates were in correlation with more rural populations. Correlation of daily prayer with smoking cigarettes, and neglect of public health recommendations for fruit and vegetable consumption and COVID-19 vaccination suggests that prayer may be substituted for preventive practices.

Age-standardized incidence-based mortality rates, and annual percent changes in primary liver cancer rates, 1978–2018.

In the period from 2018 to 2022, non-Hispanic Blacks had a colorectal cancer mortality rate of **** per 100,000 population. This statistic displays the colorectal cancer mortality rate among U.S. residents from 2018 to 2022, by race and ethnicity.

BackgroundThe neutrophil percentage-to-albumin ratio (NPAR) had been suggested as a potential prognostic biomarker in various health outcomes. However, its association with mortality in cancer survivors remains unclear.MethodsA total of 3,022 cancer survivors from the National Health and Nutrition Examination Survey (NHANES) 2005–2018 were linked to mortality outcomes from the National Death Index (NDI). Weighted Cox proportional hazards models was conducted to investigate the association between NPAR and all-cause, cancer and cardiovascular disease (CVD) mortality and the hazard ratio (HR) with 95% confidence interval (CI) were calculated. Restricted cubic spline (RCS) was used to clarify the non-linear association. Additionally, analyses for stratification and sensitivity were performed.ResultsDuring a median follow-up of 75 months, 790 all-cause deaths occurred, including 244 from cancer and 209 from CVD. After adjustment for covariates, higher NPAR was independently associated with increased risk of all-cause mortality (HR = 1.09, 95% CI = 1.06–1.13), cancer mortality (HR = 1.05, 95% CI = 0.99–1.12), and CVD mortality (HR = 1.13, 95% CI = 1.06–1.21). The RCS revealed a U-shaped relationship for all-cause and cancer mortality, with thresholds of 12.76 and 13.60, respectively. Below the threshold, higher NPAR was associated with a reduced risk of mortality (HR = 0.90, 95% CI = 0.82–0.99; HR = 0.87, 95% CI = 0.76–0.99), whereas above the threshold, the risk of mortality increased significantly (HR = 1.14, 95% CI = 1.09–1.18; HR = 1.15, 95% CI = 1.07–1.24). Subgroup and sensitivity analyses confirmed these findings.ConclusionThe U-shaped association with all-cause and cancer mortality, along with the linear association with CVD mortality, underscores the potential of NPAR as a valuable prognostic marker in cancer survivors.

In 2023, there were approximately 750.5 deaths by all causes per 100,000 inhabitants in the United States. This statistic shows the death rate for all causes in the United States between 1950 and 2023. Causes of death in the U.S. Over the past decades, chronic conditions and non-communicable diseases have come to the forefront of health concerns and have contributed to major causes of death all over the globe. In 2022, the leading cause of death in the U.S. was heart disease, followed by cancer. However, the death rates for both heart disease and cancer have decreased in the U.S. over the past two decades. On the other hand, the number of deaths due to Alzheimer’s disease – which is strongly linked to cardiovascular disease- has increased by almost 141 percent between 2000 and 2021. Risk and lifestyle factors Lifestyle factors play a major role in cardiovascular health and the development of various diseases and conditions. Modifiable lifestyle factors that are known to reduce risk of both cancer and cardiovascular disease among people of all ages include smoking cessation, maintaining a healthy diet, and exercising regularly. An estimated two million new cases of cancer in the U.S. are expected in 2025.

The Get Data Out programme from the National Disease Registration Service publishes detailed statistics about small groups of cancer patients in a way that ensures patient anonymity is maintained. The 19 cancer sites currently covered by Get Data Out are: ‘Bladder, urethra, renal pelvis and ureter’, ‘Bone’, ‘Brain’, ‘Eye’, ‘Blood cancer (haematological neoplasms)’, ‘Blood cancer (haematological neoplasm) transformations’, ‘Head and neck’, ‘Kaposi sarcoma’, ‘Kidney’, ‘Liver and biliary tract’, ‘Lung, mesothelioma, and other thoracic', Oesophagus and stomach’, ‘Ovary’, ‘Pancreas’, ‘Prostate’, ‘Sarcoma’, ‘Skin tumours’, ‘Soft tissue’, ‘Testes’. Anonymisation standards are designed into the data by aggregation at the outset. Patients diagnosed with a certain type of tumour are divided into many smaller groups, each of which contains approximately 100 patients with the same characteristics. These groups are aimed to be clinically meaningful and differ across cancer sites. For each group of patients, Get Data Out routinely publish statistics about incidence, routes to diagnosis, treatments and survival. This release covers a refresh of the 2013-2020 incidence data plus the addition of the diagnosis years 2021 and 2022 for incidence. It also covers a refresh of the 2013-2020 treatment data plus the addition of the diagnosis year 2021 for treatment statistics. It also covers a refresh of the 2013-2018 routes to diagnosis data plus the addition of the diagnosis years 2019 and 2020 for routes to diagnosis data. In this release some of our group names have been revised to more concise or more meaningful names. This better aligns us with other NDRS publications. For example, the group which was previously called 'Ovary, fallopian tube and primary peritoneal carcinomas' is now called 'Ovary', and the group which was previously called 'Haematological malignancies' is now called 'Blood cancer (haematological neoplasms)'. Finally, this release includes some new columns in the incidence data. As well as publishing crude incidence rates, we are now publishing age gender standardised incidence rates along which their upper and lower confidence intervals. This will allow for better international comparison of our groups. We have also added 50 new incidence columns which break down the incidence in the whole group by different patient characteristics. These are five-year-age and gender, broad ethnicity group, and deprivation quintile. For a specific GDO group therefore (row in our output data), a user will be able to identify the incidence for that group as a whole and then the incidence in, for example, the '65-69 male' group, the '40-44 female' group, the 'Black' group, or the 'Deprivation quintile 4' group. All releases and documentation are available on the Get Data Out dashboard. Before using the data, we recommend that you read the 'Introduction', 'FAQs' and 'Known limitations' tabs. The data is available in an open format for anyone to access and use. We hope that by releasing anonymous detailed data like this we can help researchers, the public and patients themselves discover more about cancer. If you have feedback or any other queries about Get Data Out, please email us at NDRSenquires@nhs.net and mention 'Get Data Out' in your email.

Snapshot img

Doxorubicin Market Size 2024-2028

The doxorubicin market size is valued to increase USD 497.4 million, at a CAGR of 6.09% from 2023 to 2028. Growing prevalence of cancer cases will drive the doxorubicin market.

Major Market Trends & Insights

North America dominated the market and accounted for a 48% growth during the forecast period.
By Formulation - Lyophilized powder segment was valued at USD 730.50 million in 2022
By Distribution Channel - Hospital pharmacy segment accounted for the largest market revenue share in 2022

Market Size & Forecast

Market Opportunities: USD 72.36 million
Market Future Opportunities: USD 497.40 million
CAGR from 2023 to 2028 : 6.09%

Market Summary

The market represents a significant segment in the global cancer therapeutics industry, driven by the growing prevalence of cancer cases and the introduction of precision cancer medicine. According to the World Health Organization, there were approximately 19.3 million new cancer cases and 9.9 million deaths in 2020. Doxorubicin, an anthracycline antibiotic, is a primary chemotherapeutic agent used in the treatment of various types of cancer, including breast, lung, and heart cancer. The market's evolution is influenced by several factors, including the late diagnosis and poor survival rates of patients with cancer, creating a need for more effective and targeted therapies.
Additionally, regulatory approvals and regional market dynamics contribute to the market's ongoing development. For instance, in 2020, the FDA approved Adriamycin Liposome Injection, a doxorubicin liposome injection, for the treatment of advanced or metastatic soft tissue sarcoma. This approval marked a significant milestone in the market, expanding the application scope of doxorubicin and potentially increasing market revenue.

What will be the Size of the Doxorubicin Market during the forecast period?

Get Key Insights on Market Forecast (PDF) Request Free Sample

How is the Doxorubicin Market Segmented ?

The doxorubicin industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Formulation

  Lyophilized powder
  Doxorubicin injection


Distribution Channel

  Hospital pharmacy
  Retail pharmacy
  Online pharmacy
  Others


Geography

  North America

    US
    Canada


  Europe

    Germany
    UK


  APAC

    China


  Rest of World (ROW)

By Formulation Insights

The lyophilized powder segment is estimated to witness significant growth during the forecast period.

Request Free Sample

The Lyophilized powder segment was valued at USD 730.50 million in 2018 and showed a gradual increase during the forecast period.

Request Free Sample

Regional Analysis

North America is estimated to contribute 48% to the growth of the global market during the forecast period.Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

See How Doxorubicin Market Demand is Rising in North America Request Free Sample

The market is experiencing significant growth, with North America holding the largest share in 2023. This region's dominance can be attributed to the increasing prevalence of cancer, particularly breast cancer, which is the second leading cause of cancer deaths among women in the US. According to the Centers for Disease Control and Prevention (CDC), approximately 13% of US women will develop invasive breast cancer throughout their lifetime.

This statistic underscores the substantial demand for doxorubicin, a key anticancer drug used in the treatment of various types of cancer, including breast cancer. The market's expansion is driven by the rising incidence of cancer and the drug's efficacy in cancer treatment.

Market Dynamics

Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

In The market, a significant focus lies in devising effective cardiotoxicity management strategies to mitigate the mechanisms of doxorubicin-induced cardiotoxicity. The therapeutic index of doxorubicin is a critical concern, driving the exploration of novel drug delivery approaches. Assessing doxorubicin treatment response and overcoming resistance mechanisms are essential aspects of clinical trials, which account for a substantial portion of research efforts. Pharmacokinetics and pharmacodynamics play a pivotal role in understanding doxorubicin's behavior within the body. Patient selection criteria for doxorubicin therapy are meticulously evaluated to minimize toxicities. Monitoring doxorubicin-related toxicities and implementing clini

Snapshot img

Cancer Immunotherapy Market Size 2024-2028

The cancer immunotherapy market size is valued to increase USD 45.5 billion, at a CAGR of 8.1% from 2023 to 2028. High prevalence of cancer will drive the cancer immunotherapy market.

Major Market Trends & Insights

North America dominated the market and accounted for a 43% growth during the forecast period.
By Type - Monoclonal antibodies segment was valued at USD 36.30 billion in 2022
By Application - Lung cancer segment accounted for the largest market revenue share in 2022

Market Size & Forecast

Market Opportunities: USD 99.29 billion
Market Future Opportunities: USD 45.50 billion
CAGR from 2023 to 2028 : 8.1%

Market Summary

The market represents a significant and rapidly evolving sector in the healthcare industry. This market is characterized by the adoption of advanced core technologies, including immune checkpoint inhibitors, CAR-T cell therapy, and monoclonal antibodies, which are transforming cancer treatment. Applications span various types of cancer, with a high prevalence in lung, breast, and skin cancers. Service types or product categories include biopharmaceutical companies, research institutions, and hospitals. Regulations play a crucial role, with stringent policies ensuring safety and efficacy. For instance, the US Food and Drug Administration (FDA) has approved over 20 immunotherapies since 2011. Despite challenges, such as high costs and limited accessibility, opportunities abound, including the development of combination therapies and personalized medicine. According to a recent study, the global immunotherapy market is expected to reach a 30% market share in the oncology therapeutics market by 2027.

What will be the Size of the Cancer Immunotherapy Market during the forecast period?

Get Key Insights on Market Forecast (PDF) Request Free Sample

How is the Cancer Immunotherapy Market Segmented ?

The cancer immunotherapy industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments. TypeMonoclonal antibodiesCheck point inhibitors and immunomodulatorsCancer vaccinesApplicationLung cancerBreast cancerColorectal cancerOthersGeographyNorth AmericaUSCanadaEuropeFranceGermanyAPACChinaRest of World (ROW)

By Type Insights

The monoclonal antibodies segment is estimated to witness significant growth during the forecast period.

The market continues to evolve, driven by advancements in immune cell engineering and tumor microenvironment understanding. Personalized immunotherapies, such as adoptive cell transfer and cancer cell destruction, are revolutionizing treatment. Patient response prediction relies on immunomodulatory antibodies, immunogenicity assays, and treatment response biomarkers. Progression-free survival rates have improved with oncolytic viruses, t cell activation, and cytokine therapy. Monoclonal antibodies, targeting the major histocompatibility complex, are integral to immune system stimulation, with clinical trial outcomes showing promising overall survival rates. Novel approaches include antibody-drug conjugates, cancer vaccines, and combination therapies using chimeric antigen receptors, checkpoint blockade, neoantigen targeting, and dendritic cell vaccines. Bispecific antibodies and tumor-associated antigens are also under investigation. Adverse event profiles are closely monitored to ensure safe and effective treatments. The market's continuous growth is a testament to the ongoing research and development in this field.

Request Free Sample

The Monoclonal antibodies segment was valued at USD 36.30 billion in 2018 and showed a gradual increase during the forecast period.

Request Free Sample

Regional Analysis

North America is estimated to contribute 43% to the growth of the global market during the forecast period.Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

See How Cancer Immunotherapy Market Demand is Rising in North America Request Free Sample

North America's the market holds the largest global share, primarily due to substantial investments in the oncology sector in the US. The US dominates this regional market, contributing significantly to its revenue generation. The pharmaceutical industry's considerable investments, particularly in the oncology sector, and the presence of leading pharmaceutical companies in the region underpin the US's market dominance. In the US, cancer remains one of the most prevalent chronic diseases, with approximately 436 new cases reported per 100,000 population and about 156 deaths in the same year.

Market Dynamics

Our researchers analyzed the data with 2023 as the base year, along with

Snapshot img

Cancer Diagnostics Market Size 2024-2028

The cancer diagnostics market size is valued to increase USD 17.74 billion, at a CAGR of 13.64% from 2023 to 2028. High prevalence of cancer will drive the cancer diagnostics market.

Major Market Trends & Insights

North America dominated the market and accounted for a 44% growth during the forecast period.
By End-user - Hospitals and clinics segment was valued at USD 6.71 billion in 2022
By Type - IVD segment accounted for the largest market revenue share in 2022

Market Size & Forecast

Market Opportunities: USD 220.16 million
Market Future Opportunities: USD 17744.50 million
CAGR : 13.64%
North America: Largest market in 2022

Market Summary

The market represents a significant and continually evolving sector, driven by the high prevalence of cancer worldwide. According to the World Health Organization, an estimated 19.3 million new cancer cases and nearly 10.0 million cancer deaths occurred in 2020. Core technologies, such as molecular diagnostics and imaging, are at the forefront of innovation, enabling earlier and more accurate detection. Applications, including liquid biopsies and non-invasive tests, are gaining traction due to their convenience and potential for improved patient outcomes. Service types, including laboratory testing and in-vitro diagnostics, are essential components of the market, with increasing investment in research and development (R&D) and advances in technology.
Despite these opportunities, challenges persist, including the high cost of developing companion diagnostics and navigating complex regulatory landscapes. The market's dynamics are shaped by these factors and the ongoing unfolding of regional trends, with North America and Europe leading in market share due to advanced healthcare infrastructure and robust R&D investments.

What will be the Size of the Cancer Diagnostics Market during the forecast period?

Get Key Insights on Market Forecast (PDF) Request Free Sample

How is the Cancer Diagnostics Market Segmented and what are the key trends of market segmentation?

The cancer diagnostics industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

End-user

  Hospitals and clinics
  Diagnostic laboratories


Type

  IVD
  Imaging
  LDT


Geography

  North America

    US
    Canada


  Europe

    France
    Germany


  APAC

    China


  Rest of World (ROW)

By End-user Insights

The hospitals and clinics segment is estimated to witness significant growth during the forecast period.

The market holds significant importance in the healthcare sector, delivering essential benefits to hospitals and clinics. This market's impact is felt across various levels, including enhanced patient care and satisfaction, operational efficiency at POC (Point of Care), and cost savings through strengthened operational bottom lines. In 2023, hospitals emerged as the primary revenue drivers for the market expansion. This growth can be attributed to the rising prevalence of chronic diseases, such as cervical, head and neck, lung, skin, and colorectal cancers, and the availability of skilled professionals adept at utilizing advanced diagnostic tools. These tools include circulating tumor cells analysis, cytogenetic analysis, molecular profiling, and liquid biopsy, among others.

Request Free Sample

The Hospitals and clinics segment was valued at USD 6.71 billion in 2018 and showed a gradual increase during the forecast period.

Furthermore, the ongoing pursuit of biomarker discovery, minimal residual disease detection, and personalized medicine initiatives fuel market growth. Multiplex assays, RNA sequencing, and gene expression analysis are integral to these advancements. Prognostic markers, protein biomarkers, and predictive biomarkers are crucial in therapeutic response assessment and treatment efficacy evaluation. Clinical validation, early detection, and disease progression monitoring are integral to market development. Technologies like microarray technology, DNA sequencing, next-generation sequencing, mass spectrometry, and digital pathology are continually evolving to enhance diagnostic accuracy and reduce false negative and false positive rates. Diagnostic imaging and cancer screening are also integral components of the market, ensuring optimal patient care and outcomes.

The market's future growth is expected to be driven by the increasing adoption of targeted therapies and regulatory approvals for innovative diagnostic solutions.

Request Free Sample

Regional Analysis

North America is estimated to contribute 44% to the growth of the global market during the forecast period.Technavio's analysts have elaborately explained the regional t

From 2018 to 2023, heart disease and cancer accounted for the highest share of deaths in the United States. In 2020 and 2021, COVID-19 became the third leading cause of death, accounting for around 12 percent of all deaths in 2021. However, by 2023, COVID-19 was responsible for only 1.6 percent of deaths, making it the tenth leading cause of death. This statistic shows the distribution of the 10 leading causes of death in the United States from 2018 to 2023.

According to Cognitive Market Research, The Global market for Capecitabine Tablet is increasing at a CAGR (compound annual growth rate) of 6.5% from 2023 to 2030.

Between 2023 and 2030, the market will grow at a compound yearly growth rate of 6.5%.
The global capecitabine market will experience growth throughout the forecast period due to the increase in cancer cases worldwide.
The breast cancer agent category held the biggest market share in 2023.
In terms of end user, the hospitals sector held the biggest market share in 2023.
Several factors led to North America dominating the market and contributing more than 35% of global revenue in 2023, claim the Cognitive Market Research.

Rising Oral Drug Demand and an Uptick in Cancer Cases are Driving the Market Growth

Due to the rise in cancer incidence worldwide, the global capecitabine market will expand over the course of the projected period. The market's growth would likely be boosted by oral medications. The majority of the medications in this area are available as capsules and tablets, which makes them a very practical mode of administration and is projected to accelerate the global market. New market players may have improved chances as a result of older companies' patents expiring. A primary driver of the capecitabine market's expansion is the use of combination medicines. Moreover, investments in R&D are a market addition.

According to a WHO analysis, cancer will likely be the leading cause of death worldwide in 2018, accounting for 9.6 million fatalities. Additionally, 627,000 female fatalities from breast cancer are anticipated, accounting for 15% of all female cancer deaths worldwide. As a result, the market expanded.

(Source:www.who.int/health-topics/cancer)

Market Dynamics of Capecitabine Tablet

Lack of Qualified Professionals and Rising Treatment Costs are Anticipated to Limit Market Expansion

Market expansion is expected to be constrained by a shortage of qualified specialists and escalating treatment prices. The expensive treatment options are undoubtedly a hindrance to market expansion. Many of the therapies for this illness are expensive, making them occasionally challenging for many people, particularly those living in rural areas. Thus, this may significantly hinder the market. A number of side effects linked to the medicine are preventing the worldwide capecitabine market from growing. Major side effects of the medication include anaemia, chest discomfort, diarrhoea, vomiting, weakness, blood clotting issues, and cardiac-related issues like cardiomyopathy. Pregnancy, renal disease, and DPD deficiency are some more frequent contraindications.

Impact of COVID-19 on the Capecitabine Tablets Market?

Throughout the world, the COVID-19 pandemic had a significant impact on marketplaces, changing sectors, consumer behavior, and business practices. The crisis expedited the digital transition, emphasized the need of healthcare and cleanliness, and emphasized the necessity for adaptability and resilience in difficult times. Businesses need to be flexible and sensitive to changing market conditions as the world continues to recover, all the while navigating the opportunities and challenges brought on by the pandemic's aftermath. Introduction of Capecitabine Tablet

Xeloda, the brand name under which capecitabine is sold, is a chemotherapy drug that is frequently used to treat metastatic colorectal and breast malignancies. The thymidylate synthase inhibitory effect of capecitabine stops the growth of aberrant cells. Since the healthcare industry places a high value on it, a significant increase is anticipated during the forecast period.

These innovations enable companies to provide more customised products and services, which helps the Capecitabine Tablet market flourish.

For instance, a chemotherapy medicine called capecitabine inhibits or stops the growth of cancer cells. This drug is used to treat tumours like gastric, breast, and colorectal cancer. The American Cancer Society reported that in the US, colon and rectal cancer caused expected 135,431 new cases and 50,260 fatalities in 2017.

(Source:www.ncbi.nlm.nih.gov/pmc/articles/PMC3097797/)

Age-standardized incidence (2017–2021) and death (2018–2022) rate of four major female-related cancer among the non-Hispanic White population by state, United States.

Heart disease and cancer remained the leading causes of death in the United States from 2018 to 2023. However, there have been slight changes in the 10 leading causes of death in the U.S. from 2018 to 2023. Most notable is that COVID-19 became the third leading cause of death in 2020 and 2021, but by 2023 it was the tenth leading cause. This statistic shows the rates of the 10 leading causes of death in the United States from 2018 to 2023.

BackgroundEarly-onset colorectal cancer (EOCRC) has an alarmingly increasing trend and arouses increasing attention. Causes of death in EOCRC population remain unclear.MethodsData of EOCRC patients (1975–2018) were extracted from the Surveillance, Epidemiology, and End Results database. Distribution of death was calculated, and death risk of each cause was compared with the general population by calculating standard mortality ratios (SMRs) at different follow-up time. Univariate and multivariate Cox regression models were utilized to identify independent prognostic factors for overall survival (OS).ResultsThe study included 36,013 patients, among whom 9,998 (27.7%) patients died of colorectal cancer (CRC) and 6,305 (17.5%) patients died of non-CRC causes. CRC death accounted for a high proportion of 74.8%–90.7% death cases within 10 years, while non-CRC death (especially cardiocerebrovascular disease death) was the major cause of death after 10 years. Non-cancer death had the highest SMR in EOCRC population within the first year after cancer diagnosis. Kidney disease [SMR = 2.10; 95% confidence interval (CI), 1.65–2.64] and infection (SMR = 1.92; 95% CI, 1.48–2.46) were two high-risk causes of death. Age at diagnosis, race, sex, year of diagnosis, grade, SEER stage, and surgery were independent prognostic factors for OS.ConclusionMost of EOCRC patients died of CRC within 10-year follow-up, while most of patients died of non-CRC causes after 10 years. Within the first year after cancer diagnosis, patients had high non-CRC death risk compared to the general population. Our findings help to guide risk monitoring and management for US EOCRC patients.

Prostate cancer incidence rates in the United States vary significantly across racial and ethnic groups, with Non-Hispanic Black men facing the highest risk. According to recent data, Non-Hispanic Black males have an incidence rate of 194.8 per 100,000 population, which is substantially higher than the overall rate of 120.2 per 100,000. This stark disparity highlights the importance of targeted screening and prevention efforts to address this health inequality. Incidence and mortality trends The burden of prostate cancer in the U.S. has grown in recent years. In 2025, approximately 313,780 men were projected to be diagnosed with prostate cancer, representing a significant increase from previous years. Despite this rising incidence, mortality rates have shown improvement. In 2022, the prostate cancer death rate was 18.7 per 100,000 men, compared to a rate of almost 39 per 100,000 in the year 1990. This decrease reflects advancements in treatment and early detection. Risk factors and survival rates Age remains a critical risk factor for prostate cancer, with men aged 65 to 84 having a 10.6 percent chance of developing the disease. However, there is encouraging news regarding survival rates. From 2014 to 2020, the five-year relative survival rate for prostate cancer patients in the U.S. was an impressive 97 percent. This high survival rate underscores the importance of early detection and the effectiveness of current treatment options.